Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

@article{Home2009RosiglitazoneEF,
  title={Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial},
  author={Philip D. Home and Stuart J. Pocock and Henning Beck-Nielsen and Paula Curtis and Ramon Gomis and Markolf Hanefeld and Nigel P. Jones and Michel Komajda and John J. V. McMurray},
  journal={The Lancet},
  year={2009},
  volume={373},
  pages={2125-2135}
}

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

Findings confirm the increased risk of HF events in people treated with rosiglitazone and support the recommendation that this agent should not continue to be used in people developing symptomatic HF while using the medication.

Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials

Combination therapy of metformin and sodium-glucose cotransporter-2 inhibitors is a safe and efficacious alternative for patients with type 2 diabetes who are at risk of cardiovascular comorbidity.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study

In patients with T2D failing prior hypoglycemic therapies, Pio combinations with SU or Met (especially Pio + Met) improved blood lipid and glycemic profiles, decreasing the proportion of patients with a high microvascular or macrovascular risk.

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials

The malignancies rates in these two randomised controlled clinical trials do not support a view that metformin offers any particular protection against malignancy compared with rosiglitazone, but they do not refute the possibility of a difference compared with sulfonylureas.

Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Meta-analysis supported pioglitazone as an effective treatment option for T2DM patients to ameliorate hyperglycaemia, adverse lipid metabolism and blood pressure.

Cardiovascular safety and efficacy of combination therapy with metformin and sodium-glucose cotransporter-2 inhibitors versus metformin and sulfonylureas in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

A combination therapy of metformin and sodium-glucose cotransporter-2 inhibitors is a safe and efficacious alternative to combination Therapy of met formin and sulphonylureas for patients with type 2 diabetes who are at risk of cardiovascular comorbidity.

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

Compared to rosiglitazone 4 mg plus glimepiride, liraglutide is a cost-effective treatment option for improving glucose control in T2DM, particularly at the 1.2-mg dose.

Database Evaluation of the Effects of Long‐Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes

In this community‐based cohort, 30 months of therapy with rosiglitazone treatment was associated with increased risk of CHF but was not associated withincreased risk of AMI, ACS, coronary revascularization, or all‐cause mortality.
...

References

SHOWING 1-10 OF 23 REFERENCES

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)

Changes in BP were not accompanied by compensatory increases in heart rate, did not correlate with basal insulin sensitivity estimates and were not explained by changes in antihypertensive therapy between the various strata.

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

The RECORD study should provide robust data on the extent to which rosiglitazone, in combination with metformin or sulphonylurea therapy, affects CV outcomes and progression of diabetes in the long term.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

The interim findings from this ongoing study were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalization or death from cardiovascular causes.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes mellitus as well as the availability of outcome data for myocardial infarction and death from cardiovascular causes.

10-year follow-up of intensive glucose control in type 2 diabetes.

Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up.

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone use for at least 12 months is associated with a significantly increased risk of myocardial infarction and heart failure, without a significantlyIncreased risk of cardiovascular mortality.